These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 1220976)
1. R17934-NSC238159: a new antitumor drug--II. Effect on mitotic cycle of L1210 leukemia cells in vivo and synergism with cytosine arabinoside (NSC63878). Atassi G; Schaus C; Tagnon HJ Eur J Cancer (1965); 1975 Sep; 11(9):609-14. PubMed ID: 1220976 [No Abstract] [Full Text] [Related]
2. R17934-NSC 238159: a new antitumor drug--I. Effect on experimental tumors and factors influencing effectiveness. Atassi G; Tagnon HJ Eur J Cancer (1965); 1975 Sep; 11(9):599-607. PubMed ID: 1220975 [No Abstract] [Full Text] [Related]
3. Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213. Rivera G; Avery T; Roberts DW Eur J Cancer (1965); 1975 Sep; 11(9):639-47. PubMed ID: 1220978 [No Abstract] [Full Text] [Related]
4. Influence of mitotic cycle inhibitors on the antileukemic activity of cytosine arabinoside (NSC-63878) in mice bearing leukemia L1210. Vadlamudi S; Goldin A Cancer Chemother Rep; 1971 Dec; 55(5):547-55. PubMed ID: 5159846 [No Abstract] [Full Text] [Related]
5. Combination chemotherapy with cytosine arabinoside, L-asparaginase, and 6-azauridine for transplantable murine leukemias. Avery TL; Roberts D Cancer Res; 1973 Apr; 33(4):791-9. PubMed ID: 4696479 [No Abstract] [Full Text] [Related]
6. Antitumor effect and mode of action of 1-beta-D-arabinofuranosylcytosine 5'-phosphate in leukemia L1210. Schrecker AW; Goldin A Cancer Res; 1968 Apr; 28(4):802-3. PubMed ID: 5649067 [No Abstract] [Full Text] [Related]
7. Use of cell-cycle information in the preparation of drug combinations: results with cytosine arabinoside plus actinomycin D1,2. Bhuyan BK; Fraser TJ; Day KJ Cancer Treat Rep; 1976 Dec; 60(12):1813-8. PubMed ID: 1036090 [TBL] [Abstract][Full Text] [Related]
8. [Clinical and animal experiment studies on the cell-cycle arrest using cytosine arabinoside in leukemias]. Büchner T; Barlogie B; Hiddemann W; Hofschröer J; Metz U; Ortheil NB; Kamanabroo D; Asseburg U Verh Dtsch Ges Inn Med; 1975; 81():1112-4. PubMed ID: 1065151 [No Abstract] [Full Text] [Related]
9. Effect and toxicity of combination treatment including cyclocytidine or cytosine arabinoside in L-1210 and sarcoma-180 systems. Hoshi A; Kanzawa F; Iigo M; Kuretani K Gan; 1975 Oct; 66(5):539-46. PubMed ID: 1220992 [TBL] [Abstract][Full Text] [Related]
10. Optimum scheduling during combination chemotherapy of murine leukemia. Additional examples of schedule-dependent synergism between S-phase-specific antimetabolites and agents inducing mitotic or pre-mitotic (G2) arrest. Sirotnak FM; Schmid FA; Temple C; Montgomery JA Cancer Chemother Pharmacol; 1983; 11(3):205-7. PubMed ID: 6640829 [TBL] [Abstract][Full Text] [Related]
11. Dose-related synergism of cytosine arabinoside and methotrexate against murine leukemia L1210. Avery TL; Roberts D Eur J Cancer (1965); 1974 Jul; 10(7):425-9. PubMed ID: 4457345 [No Abstract] [Full Text] [Related]
12. A new anti-cancer principle isolated from Gymnosporia rothiana Laws, and its use in attaining cures in L1210 leukaemia in combination with "S" phase sensitive drugs. Alate AD; Khandalekar DD; Amonkar AJ; Adwankar MK; Sahasrabudhe MB Biomedicine; 1978 Oct; 28(5):270-3. PubMed ID: 743552 [TBL] [Abstract][Full Text] [Related]
13. Cytosine arabinoside (NSC-63878)--clinical brochure. Livingston RB; Carter SK Cancer Chemother Rep 3; 1968 Dec; 1(1):179-205. PubMed ID: 4989814 [No Abstract] [Full Text] [Related]
14. Pharmacological and physicochemical properties of a new anthracycline with potent antileukemic activity. Nafziger J; Auclair C; Florent JC; Guillosson JJ; Monneret C Leuk Res; 1991; 15(8):709-13. PubMed ID: 1654481 [TBL] [Abstract][Full Text] [Related]
15. SYNERGISM OF THE ANTINEOPLASTIC ACTIVITY OF CYTOSINE ARABINOSIDE BY PORFIROMYCIN. EVANS JS; BOSTWICK L; MENGEL GD Biochem Pharmacol; 1964 Jul; 13():983-8. PubMed ID: 14201140 [No Abstract] [Full Text] [Related]
16. Collateral sensitivity of resistant lines of mouse leukemias L1210 and L5178Y. Schmid FA; Hutchison DJ Cancer Res; 1972 Apr; 32(4):808-12. PubMed ID: 5014791 [No Abstract] [Full Text] [Related]
17. [Selective treatment of leukemia L1210 with combination of deoxycytidine and lethal doses of cytosine arabinoside]. Bukhman VM; Lichinitser MR; Svet-Moldavskiĭ GIa; Mkheidze DM Biull Eksp Biol Med; 1978 Mar; 85(3):340-3. PubMed ID: 276385 [TBL] [Abstract][Full Text] [Related]
18. [Experimental study on the correlation between the antitumor activity and pharmacokinetics of cytosine arabinoside (Ara-C) and N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC)]. Takenaka T; Kimura K Nihon Gan Chiryo Gakkai Shi; 1985 Dec; 20(10):2322-8. PubMed ID: 3831176 [No Abstract] [Full Text] [Related]
19. [Cross-resistance of HO-221 and various antitumor agents in sublines of mouse leukemia]. Nakajima T; Masuda H; Okamoto T; Watanabe M; Yokoyama K; Yamada N; Fujimoto S; Tsukagoshi S; Taguchi T Gan To Kagaku Ryoho; 1991 Feb; 18(2):201-9. PubMed ID: 1899547 [TBL] [Abstract][Full Text] [Related]
20. Effect of FK973, a new antitumor antibiotic, on the cell cycle of L1210 cells in vitro. Nakamura T; Masuda K; Matsumoto S; Oku T; Manda T; Mori J; Shimomura K Jpn J Pharmacol; 1989 Mar; 49(3):317-24. PubMed ID: 2501546 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]